

BENITEC FILES STATEMENT OF APPEAL TO GRAHAM PATENT IN EUROPE

- **Statement of Appeal to Graham EP1555317 patent**
- **EPO opposition hearing for Graham EP1624060 patent**

Sydney, Australia, 25 November 2014: Benitec Biopharma Limited (ASX: BLT, OTC: BTEBY) advises that a Statement of Appeal has been filed with the European Patent Office (EPO). The Statement provides the substantive arguments to support the basis for appealing the EPO's revocation decision of the Graham EP patent 1555317 at the opposition hearing of 22 May 2014. The decision to appeal was announced on 22 September 2014, entitled "Benitec appeals Graham patent revocation in Europe".

CEO and Managing Director of Benitec Biopharma, Dr Peter French, said, "Benitec and CSIRO have worked closely on the preparation of the Statement and we are confident that it provides very strong grounds for the Graham patent to be reinstated in Europe. It should be noted that whilst Benitec and CSIRO continue to work together to protect our position around the foundational ddRNAi patents, Benitec is building its own robust intellectual property portfolio to protect its competitive position in ddRNAi in general and in the specific pipeline programs under development."

The EPO has advised that the next Graham patent opposition (EP1624060) will be heard in early 2015. EP1624060 is opposed by BASF SE (Germany). The hearing will be held in Rijswijk (Netherlands).

Ms Sakura Holloway, IP Counsel at Benitec, commented, "The key difference between the two EP Graham patents is in the length of the expressed RNA. However, many of the arguments that have been developed in the Statement of Appeal for EP1555317 are also relevant to the second Graham patent, with positive outcomes expected in both cases."

For more information, please contact the persons below or visit the Company's website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX: BLT, OTC: BTEBY) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies for applications including HIV/AIDS, retinitis pigmentosa, chronic pain and Huntington's disease. For more information refer to the Company's website at www.benitec.com.